PMID- 37032609
OWN - NLM
STAT- MEDLINE
DCOM- 20230411
LR  - 20230419
IS  - 1473-2300 (Electronic)
IS  - 0300-0605 (Print)
IS  - 0300-0605 (Linking)
VI  - 51
IP  - 4
DP  - 2023 Apr
TI  - Correlation of signal transducer and activator of transcription-3 and beta-catenin 
      expression in laryngeal squamous cell carcinoma.
PG  - 3000605231166228
LID - 10.1177/03000605231166228 [doi]
LID - 03000605231166228
AB  - OBJECTIVE: The specific roles of phosphorylated signal transducer and activator 
      of transcription-3 (p-STAT3) and beta-Catenin in laryngeal squamous cell carcinoma 
      (LSCC) remain unclear. METHODS: In this study, the correlations between p-STAT3, 
      beta-Catenin, and clinicopathological characteristics were investigated using 
      tissues and clinical data from 124 LSCC cases. Immunohistochemistry and 
      immunofluorescence assays were used to examine p-STAT3 and beta-Catenin expression 
      and localization in these samples. Kaplan-Meier survival and Cox regression 
      analyses were performed to evaluate the prognostic significance of these 
      proteins. LSCC cell lines were treated with a STAT3 inhibitor 
      (dihydroartemisinin) or activator (interleukin-6) to explore the mechanism of 
      p-STAT3 and beta-Catenin. RESULTS: There was an inverse correlation between p-STAT3 
      and beta-Catenin expression in the LSCC samples. Patients with high p-STAT3 and low 
      beta-Catenin expression levels had significantly worse overall survival. 
      Multivariate Cox regression analysis revealed that lymph node metastasis and 
      beta-Catenin expression were both independently correlated with unfavorable overall 
      survival. Cell treatment with the p-STAT3 inhibitor inhibited the nuclear 
      accumulation of beta-Catenin, while p-STAT3 activator treatment could promote 
      beta-Catenin translocation to the nucleus. CONCLUSION: Overall, our data indicate 
      that p-STAT3 expression is associated with LSCC by promoting beta-Catenin 
      degradation.
FAU - Sun, Yajing
AU  - Sun Y
AD  - Graduate School of Hebei Medical University, Shijiazhuang, Hebei Province, China.
FAU - Lu, Xiuying
AU  - Lu X
AD  - Department of Otolaryngology Head and Neck Surgery, Bethune International Peace 
      Hospital, Shijiazhuang, Hebei Province, China.
FAU - Li, Hui
AU  - Li H
AD  - Department of Pathology, Bethune International Peace Hospital, Shijiazhuang, 
      Hebei Province, China.
FAU - Li, Xiaoming
AU  - Li X
AUID- ORCID: 0000-0002-0931-727X
AD  - Graduate School of Hebei Medical University, Shijiazhuang, Hebei Province, China.
AD  - Department of Otolaryngology Head and Neck Surgery, Bethune International Peace 
      Hospital, Shijiazhuang, Hebei Province, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Int Med Res
JT  - The Journal of international medical research
JID - 0346411
RN  - 0 (beta Catenin)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Humans
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - *Laryngeal Neoplasms/genetics
MH  - *Carcinoma, Squamous Cell/metabolism
MH  - beta Catenin/genetics/metabolism
MH  - Prognosis
MH  - *Head and Neck Neoplasms
MH  - Biomarkers, Tumor/analysis
PMC - PMC10107985
OTO - NOTNLM
OT  - STAT3
OT  - biomarker
OT  - epithelial-mesenchymal transition
OT  - laryngeal squamous cell carcinoma
OT  - prognostic indicator
OT  - beta-Catenin
COIS- The authors declare that there is no conflict of interest.
EDAT- 2023/04/11 06:00
MHDA- 2023/04/11 06:42
PMCR- 2023/04/09
CRDT- 2023/04/10 03:03
PHST- 2023/04/11 06:42 [medline]
PHST- 2023/04/10 03:03 [entrez]
PHST- 2023/04/11 06:00 [pubmed]
PHST- 2023/04/09 00:00 [pmc-release]
AID - 10.1177_03000605231166228 [pii]
AID - 10.1177/03000605231166228 [doi]
PST - ppublish
SO  - J Int Med Res. 2023 Apr;51(4):3000605231166228. doi: 10.1177/03000605231166228.